Introducing
Repair. Rejuvenate. Regrow. Naturally.
ExoGain is an advanced regenerative therapy that combines autologous exosomes with a rich concentration of growth factors to support natural tissue repair, cellular regeneration, and rejuvenation. Prepared from the patient's own blood, ExoGain provides a personalized and biocompatible solution for aesthetic and regenerative applications.
Redefining Regenerative Aesthetics
Developed using cutting-edge biotechnology, ExoGain harnesses your own body's healing intelligence to restore, rejuvenate, and regenerate — naturally.
Nanosized vesicles enriched with mRNA, proteins, and lipids that communicate regenerative signals between cells, activating stem cells and accelerating repair.
Platelets precisely activated to release high levels of PDGF, VEGF, EGF, and FGF — enhancing angiogenesis, collagen synthesis, and tissue regeneration.
ExoGain™ is designed to enable direct cell-to-cell signalling — something conventional PRP or GFC alone does not provide — with the aim of supporting deeper rejuvenation.
ELISA assay
Measured concentrations in the final ExoGain preparation, quantified by sandwich ELISA.
| Growth factor | Concentration | Unit | Primary role |
|---|---|---|---|
| PDGF | 99,443.75 | pg/ml | Fibroblast activity, tissue repair |
| VEGF | 3,899 | pg/ml | Angiogenesis, microcirculation |
| bFGF | 2,793 | pg/ml | Cell proliferation, follicular support |
| TGF-β | 1,732.50 | pg/ml | Collagen synthesis, remodelling |
| EGF | 550 | pg/ml | Epithelial proliferation, wound healing |
ELISA analysis confirms the growth factor content of each ExoGain preparation — PDGF, VEGF, EGF, TGF-β and bFGF. Consistent biomarker enrichment is what the preparation protocol is designed to deliver, batch to batch.
Together, these bioactive nanocarriers and regenerative proteins are designed to provide a higher concentration of regenerative signals than conventional PRP or GFC preparations. Analytical composition data describes what is in the product, not clinical outcome — see clinical evidence.
Clinical applications
Chairside preparation
Six steps, from venous draw to filtered autologous product.
Head to head
| Parameters | PRP | GFC | EXOS-GFC |
|---|---|---|---|
| Composition | Platelets with plasma | Platelet-derived growth factors | Autologous exosomes + growth factors |
| Mechanism | Indirect GF release | Direct GF delivery | Direct cellular communication + potent regenerative signaling |
| Regenerative capacity | Moderate | Improved | Designed to target inflammation and stimulate regeneration |
| Purity | Contains RBCs/WBCs | Contains cell debris | RBC-free, cell-free, highly purified exosomes |
| Onset of results | 4–6 weeks | 2–3 weeks | 1–2 weeks |
Source: Comparison compiled from the ExoGain product brochure (EXG-BRC-01-25062026, Rev-01). Onset ranges are indicative and vary by patient, indication and protocol; they are not derived from a head-to-head controlled trial.
Nanoparticle Tracking Analysis (NTA)
Nanoparticle Tracking Analysis is a technique used to measure the size distribution and concentration of nanoparticles, including exosomes. NTA combines the principles of laser light scattering and Brownian motion to provide detailed insight into exosome populations.
2.05e+13 particles/ml
Original exosome concentration.
85.7% of particles between 30–150 nm, with a therapeutic peak at 100 nm.
>98% exosome and growth factor content with negligible impurities. NTA supports batch-to-batch consistency of the preparation.
Source: Nanoparticle Tracking Analysis, [instrument / model] at [testing laboratory, city], report no. [report no.], [test date], n = [n] samples. Full report available to clinicians on request.
Clinical evidence
ExoGain is currently being evaluated in a prospective, open-label clinical study assessing hair growth and hair quality outcomes in subjects with hair thinning or early androgenic alopecia.
Recruiting
15 of 40 planned subjects enrolled
Enrolment is open. This figure is updated as the study progresses.
Results will be published on completion of the study. This page will be updated as the study progresses. Until then, no efficacy claim on this page is supported by published outcome data — the figures shown elsewhere on this page describe the product’s measured composition, not its clinical effect.
Safety
ExoGain is prepared from the patient’s own blood at the point of care. Its safety profile follows from that.
Every dose is derived from the patient’s own venous blood. There is no donor-derived, animal-derived or cultured cell material, and therefore no risk of immune rejection or cross-donor transmission.
The kit is sterile and single-use. Tubes, syringes and the filter are discarded after one preparation; nothing is pooled, stored or reused between patients.
Reactions are those of the venous draw and the injection itself — transient soreness, redness, swelling or minor bruising at the draw or treatment site, typically settling within a few days.
To be prepared and administered by a qualified healthcare professional trained in the protocol. Aseptic technique throughout; the preparation is used chairside and not stored.
Approved by the Central Drugs Standard Control Organisation, India. Manufacturing licence no. MFG/MD/2025/000469.
Refer to the Instructions for Use supplied with the kit for the full list of contraindications, warnings and precautions, including patient selection criteria.
Safety reporting: [adverse-event statement for the ongoing study, as of (date) — supply or delete this sentence] Clinicians should report any suspected adverse event to info@exogain.in.
Send us your details and we will come back with pricing, the full preparation protocol, the assay reports and training options.
What ships
Approved by the Central
Drugs Standard Control Organisation, India.
Downloads
For clinicians and distribution partners. Assay reports and the Instructions for Use are sent on request — use the enquiry form below.
The full product brochure — science, indications, preparation protocol, comparison against PRP and GFC, assay data and kit contents.
Download PDFThe full ELISA growth factor report and the Nanoparticle Tracking Analysis report, for clinicians who want the underlying data behind the figures on this page.
Request the reportsPreparation steps, aseptic technique, contraindications, warnings and precautions. Supplied with every kit and available in advance to clinicians evaluating the product.
Request the IFUGet in touch
For clinicians, clinics and distribution partners. Tell us a little about your practice and we will send pricing, the full protocol and training details.
Kamal Encon Industries Limited
6th Floor, Antriksh Bhawan
Kasturba Gandhi Marg, New Delhi – 110001
India
